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Background: Pathogenic sarcomere mutations are found in about 50% of hypertrophic cardiomyopathy (HCM) patients. Currently, clear 
genotype-phenotype relations are lacking. This study compares phenotype and outcome in genotype positive (G+) and genotype negative 
(G-) HCM.
methods: Between January 2004 and 2012, 431 HCM patients were included at our outpatient clinic. 100 patients (23%) refused genetic 
testing and were excluded. Kaplan Meier curves and cox-regression analyses were used for statistical analyses.
results: Of 331 HCM patients (34% female), 192 (58%) were G+. The G+ group was younger (40 vs 47 years, p<0.001) and less 
symptomatic (NYHA I: 50 vs 24%, p<0.001).) The G- patients had higher left ventricular outflow tract gradients (74 vs 12 mmHg, p<0.001) 
and underwent more septal reduction procedures (54 vs 29%, p<0.001). During the 7 ± 2.4 year follow-up, the heart failure related mortality 
was higher in the G+ group (9 vs 2%, p=0.03, figure 1). End diastolic LV diameter (HR 1.1, p=0.001) and pathogenic mutation (HR 2.9, 
p=0.006) were independent risk factors for all-cause mortality.
conclusion:  Although G+ HCM patients are less symptomatic, they have a higher risk of death, mainly due to heart failure. This suggests 
that sarcomeric dysfunction precludes toward adverse cardiac outcome.
 
